Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
1.250
-0.090 (-6.72%)
Mar 18, 2026, 2:20 PM EDT - Market open

Serina Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
0.120.063.150.030.140.36
Revenue Growth (YoY)
-96.33%-98.22%9173.53%-76.39%-60.11%-79.11%
Cost of Revenue
---0.010.020.03
Gross Profit
0.12--0.020.130.34
Selling, General & Admin
11.369.623.895.976.716.72
Research & Development
12.127.482.391.031.463.71
Other Operating Expenses
-----0.11-
Total Operating Expenses
23.4817.16.2878.0610.44
Operating Income
-23.36-17.05-3.13-6.98-7.93-10.1
Interest Expense
-0.03-0.53-0.56-3.34-1.1-0.4
Other Non-Operating Income (Expense)
4.776.378.96-0.210.450.11
Total Non-Operating Income (Expense)
4.735.848.4-3.55-0.65-0.3
Pretax Income
-18.63-11.215.27-10.52-8.58-10.4
Net Income
-18.59-11.145.27-10.46-8.68-10.87
Minority Interest in Earnings
-0.05-0.07--0.06-0-0.01
Earnings From Discontinued Operations
-----0.21-1.3
Net Income to Common
-18.59-11.145.27-10.46-8.68-10.87
Shares Outstanding (Basic)
1072211
Shares Outstanding (Diluted)
1077211
Shares Change (YoY)
28.74%0.11%242.70%99.12%0.58%1.07%
EPS (Basic)
-1.87-1.512.36-1.25-8.09-10.20
EPS (Diluted)
-1.87-1.510.73-1.25-8.09-10.20
Free Cash Flow
-16.58-17.16-2.98-5.94-15.62-15.85
Free Cash Flow Per Share
-1.69-2.33-0.41-2.77-14.50-14.79
Gross Margin
100.00%100.00%100.00%61.76%86.81%92.80%
Operating Margin
-20141.38%-30442.86%-99.24%-20514.71%-5509.03%-2797.78%
Profit Margin
-20218.10%-20012.50%167.11%-30947.06%-6031.25%-3040.44%
FCF Margin
-14288.79%-30641.07%-94.51%-17467.65%-10847.22%-4389.20%
EBITDA
-23.04-16.63-2.87-6.84-7.8-8.85
EBITDA Margin
-19857.76%-29691.07%-90.87%-20126.47%-5418.06%-2450.14%
EBIT
-23.36-17.05-3.13-6.98-7.93-10.1
EBIT Margin
-20141.38%-30442.86%-99.24%-20514.71%-5509.03%-2797.78%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q